文献速递甲状腺疾病

2000至2017年加利福尼亚州甲状腺癌发病率与基于发病率的死亡率上升趋势

Rising Incidence and Incidence-Based Mortality of Thyroid Cancer in California, 2000-2017.
PubMed 文献 · J Clin Endocrinol Metab · 2020-01-01

该研究基于加利福尼亚癌症登记处2000至2017年回顾性分析全部甲状腺癌病例,共纳入69684例(女性76%,中位年龄50岁)。结果显示甲状腺癌发病率从6.43/10万人年升至11.13/10万人年(年均增长4%,P<0.001),所有组织学亚型和所有肿瘤大小均见增加;甲状腺癌特异性死亡率年均增长1.7%(P<0.001),男性(年均2.7%)和较大肿瘤(2-4 cm,年均3.4%)中增幅更大。

要点

  • 甲状腺癌发病率从6.43升至11.13/10万人年,年均增长4%(P<0.001),所有组织学亚型和肿瘤大小均增加。
  • 甲状腺癌特异性死亡率年均增长1.7%(P<0.001),男性年均增长2.7%,2-4 cm肿瘤患者年均增长3.4%。
  • 所有大小甲状腺癌发病率上升且男性及较大肿瘤死亡率增加,提示临床显著疾病真实增加。

核心结论

  • 全州登记数据显示甲状腺癌发病率增加且不限于小型乳头状甲状腺癌,所有大小甲状腺癌发病率上升伴男性及较大肿瘤患者基于发病率的死亡率增加,提示临床显著疾病的真实增加。

研究设计与样本

  • 回顾性分析加利福尼亚癌症登记处2000至2017年报告的全部甲状腺癌病例,共69684例(女性76%,中位年龄50岁),采用对数线性模型估计年龄调整发病率和基于发病率的死亡率的年度百分比变化。

主要发现

  • 甲状腺癌发病率从6.43/10万人年升至11.13/10万人年,年均增长4%(P<0.001),所有组织学亚型(乳头状、滤泡状、髓样、未分化)和所有肿瘤大小均增加。
  • 甲状腺癌特异性死亡率年均增长1.7%(P<0.001)。
  • 男性死亡率年均增长2.7%(P<0.001),大于总体1.7%。
  • 较大肿瘤(2-4 cm)患者死亡率年均增长3.4%(P<0.05),大于总体1.7%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: The increased incidence of thyroid cancer globally over the past several decades is principally attributed to small, indolent papillary thyroid cancers. A possible concomitant increase in thyroid cancer-specific mortality remains debated. OBJECTIVE: The changes in thyroid cancer incidence and incidence-based mortality were assessed using a large population-based cohort over an 18-year period. DESIGN & PATIENTS: A retrospective analysis of all thyroid cancers reported in the California Cancer Registry was performed (2000-2017). Age-adjusted incidence and incidence-based mortality rates were analyzed using a log-linear model to estimate annual percent change. RESULTS: We identified 69 684 individuals (76% female, median age 50 years) diagnosed with thyroid cancer. The incidence of thyroid cancer increased across all histological subtypes (papillary, follicular, medullary, and anaplastic) and all tumor sizes. The incidence increased from 6.43 to 11.13 per 100 000 person-years (average increase 4% per year; P < 0.001) over the study period. Thyroid cancer-specific mortality rates increased on average by 1.7% per year (P < 0.001). The increased mortality rates were greater in men (2.7% per year, P < 0.001) and patients with larger tumors (2-4 cm) (3.4% per year, P < 0.05). CONCLUSIONS: Data from this statewide registry demonstrate that the incidence of thyroid cancer is increasing, and that this phenomenon is not restricted to small papillary thyroid cancers. Rising incidence in thyroid cancers of all sizes with concurrent increase of incidence-based mortality in men and those with larger tumors suggest a true increase in clinically significant disease.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Yan KL, Li S, Tseng CH, et al. Rising Incidence and Incidence-Based Mortality of Thyroid Cancer in California, 2000-2017. J Clin Endocrinol Metab. 2020. PMID: 32166320. doi:10.1210/clinem/dgaa121

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。